Pharmaceutical Company Collaborations
Disease Foundation Collaborations
National Institutes of Health Grants
CombinatoRx collaborates with pharmaceutical and biotechnology companies to support the full development and commercialization of selected product candidates to obtain access to additional development, financial or commercial resources including sales forces. Pharmaceutical Corporations CollaborationsFovea Pharmaceuticals SAIn January 2006, CombinatoRx entered into a research and license agreement with Fovea Pharmaceuticals in which Fovea agreed to fund and develop selected CombinatoRx product candidates for ophthalmic diseases up to the start of Phase III trials (Full News Release). In exchange for Fovea's development investment, CombinatoRx will grant Fovea exclusive commercial rights to these products in Europe and certain additional countries. CombinatoRx will retain commercialization rights to North America. The companies will have co-exclusive rights in Japan and Taiwan. Separately, CombinatoRx licensed to Fovea an exclusive worldwide right to certain preclinical drug combinations to treat specified indications. CombinatoRx is eligible to receive up to $20 million in upfront and milestone payments for the first product, an additional milestone payment for the approval of a product in an additional indication, and royalties on cumulative net sales. Angiotech Pharmaceuticals, Inc.In June 2007, Angiotech Pharmaceuticals, Inc. extended their collaboration with CombinatoRx based upon the successful advancement of a number of product candidates in relevant preclinical models. The joint research being conducted under the agreement to create next generation drug device and local medicines has been extended beyond the initial two and a half year term to a total of five years, resulting in a $7 million payment to CombinatoRx due before October 3, 2007 (Full News Release). In October 2005, CombinatoRx and Angiotech entered into a research and license agreement which granted Angiotech an option to evaluate and exclusively license compounds selected by Angiotech from the CombinatoRx clinical and preclinical pipeline and its proprietary bioinformatics database of synergistic combination pharmaceuticals for development and potential commercialization in certain medical device and local interventional applications (Full News Release). CombinatoRx also agreed to deploy its proprietary combination High Throughput Screening (cHTS™) technology in a joint multi-year research initiative to identify novel drug combinations for multiple areas of strategic importance to Angiotech. Intellectual property from this research project will be jointly owned, and exclusively cross licensed to CombinatoRx for traditional pharmaceutical uses outside the Angiotech fields of use. Under the terms of the agreement, Angiotech has made an upfront license execution payment of $27 million to CombinatoRx plus a $15 million equity investment in CombinatoRx entitling Angiotech to license up to ten CombinatoRx compounds for the Angiotech field, and up to five more compounds for an additional payment of $2 million per compound. Intellectual property from the research project component of the agreement is exclusively licensed to Angiotech in the Angiotech fields of use. CombinatoRx is eligible to receive development and regulatory milestone payments of up to $30 million for each product selected by Angiotech for development, in addition to royalties on cumulative commercial sales of such products. Bio*One Capital Pte. Ltd.In August 2005, CombinatoRx formed a subsidiary in Singapore, CombinatoRx Singapore Pte. Ltd., to discover and develop novel combination drug candidates to treat infectious diseases by leveraging its cHTS™ platform (Full News Release). In partnership with Bio*One Capital, CombinatoRx Singapore is eligible to receive up to $20 million in financing plus grants which will be used to establish and develop preclinical and clinical development capabilities and for the development of novel drug candidates to treat infectious diseases. CombinatoRx and Bio*One each own 51% and 49% of CombinatoRx Singapore respectively and CombinatoRx has the option to buy back Bio*One's interest. Disease Foundation CollaborationsCystic Fibrosis Foundation Therapeutics (CFFT)In June 2006, CombinatoRx entered into a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to discover and develop novel therapeutics built from synergistic drug combinations to treat cystic fibrosis (CF). (Full News Release). Under the terms of the agreement, CFFT will award CombinatoRx up to $13.8 million in research expenses and will also fund up to 75% of clinical development expenses through Phase 2a on the first potential product candidate, provided both parties agree to commence clinical development. In addition, CombinatoRx will retain full worldwide commercialization rights, receive payments upon successful completion of certain clinical and regulatory milestones, and own new intellectual property generated during the collaboration. CFFT will be eligible to receive royalties from CombinatoRx on net sales of any approved products. CHDIIn August 2005, CombinatoRx entered into a research agreement with CHDI, Inc., a foundation that is seeking to rapidly discover and develop drugs to prevent or slow progression of Huntington's disease (HD), a genetic neurodegenerative disease. Through this collaboration, CombinatoRx and CHDI will jointly perform research and development with the intention to discover and perform preclinical development of product candidates for the treatment of Huntington's disease. Under the terms of the collaboration, CombinatoRx will receive up to $6 million in research and development funding over the next four years. CombinatoRx and CHDI will jointly own all intellectual property on product candidates discovered during the collaboration. Accelerate Brain Cancer Cure (ABC2)In September 2004, CombinatoRx announced a sponsored research collaboration with Accelerate Brain Cancer Cure (ABC2) (Full News Release). This collaboration utilized CombinatoRx's proprietary combination High Throughput Screening (cHTS™) technology in an effort to discover therapeutic drug combinations that hit multiple targets relevant to glioblastoma multiforme, a deadly form of brain cancer. CombinatoRx received research funding from ABC2 and the intellectual property and commercial rights to all product candidates discovered during the collaboration. Spinal Muscular Atrophy Foundation (SMA)In August 2004, CombinatoRx entered into a sponsored research agreement with Spinal Muscular Atrophy Foundation (SMA Foundation), applying the CombinatoRx cHTS™ technology in an effort to discover innovative drug combinations that upregulate SMN protein levels (Full News Release). CombinatoRx received research and development funding and owns all intellectual property and commercial rights to any discovered product candidates. National Institutes of Health GrantsNational Institute of Allergy and Infectious Diseases (NIAID)In April 2005, CombinatoRx was awarded a $4.4 million research grant from the National Institute of Allergy and Infectious Diseases (NIAID) (Full News Release). This cooperative research grant with the National Institute of Health (NIH) will apply the CombinatoRx cHTS™ technology to identify potential anti-toxin therapeutics that could be used to alleviate the life-threatening symptoms associated with anthrax exposure. National Institute of Neurological Disorders and StrokeIn August 2005, as part of the Company's on-going research targeting new treatments for neurodegenerative disease, CombinatoRx began a subcontract with Science Applications International Corporation (SAIC) where CombinatoRx acts as the in vitro bioassay screening facility for the Spinal Muscular Atrophy Project established by the National Institute of Neurological Disorders and Stroke (NINDS). CombinatoRx is receiving 2 years of research and development funding under the subcontract. If you have business development inquiries, please contact bizdev@combinatorx.com. |
|
|
 |
